My patents showcase innovations in both small-molecule drug discovery and antibody design in therapeutic discovery.

Cancer therapies are undergoing a seismic shift with patents emerging that unlock new molecular vulnerabilities. Among the most promising are compounds designed to disable WRN helicase, a DNA repair enzyme uniquely essential to cancers exhibiting microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). These inventions strike at the heart of tumor survival while sparing healthy cells, offering hope in settings where immunotherapies or chemotherapy resistance prevail.

Alongside these inhibitors, novel antibody approaches—such as those targeting mutant calreticulin—extend the toolkit of selective, mechanism-driven cancer therapeutics.

Collectively, these patents mark a decisive step toward precision oncology.